
Joaquin A Vizcarra

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7327265/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A roadmap for implementation of patientâ€centered digital outcome measures in Parkinson's disease obtained using mobile health technologies. Movement Disorders, 2019, 34, 657-663.	2.2	213
2	Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. Neurology, 2019, 92, 329-337.	1.5	194
3	Vascular <scp>P</scp> arkinsonism: <scp>D</scp> econstructing a <scp>S</scp> yndrome. Movement Disorders, 2015, 30, 886-894.	2.2	88
4	Orthostatic hypotension and REM sleep behaviour disorder: impact on clinical outcomes in α-synucleinopathies. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1257-1263.	0.9	73
5	Integration of technology-based outcome measures in clinical trials of Parkinson and other neurodegenerative diseases. Parkinsonism and Related Disorders, 2018, 46, S53-S56.	1.1	63
6	Association of Subthalamic Deep Brain Stimulation With Motor, Functional, and Pharmacologic Outcomes in Patients With Monogenic Parkinson Disease. JAMA Network Open, 2019, 2, e187800.	2.8	54
7	Risk of spread in adult-onset isolated focal dystonia: a prospective international cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 314-320.	0.9	50
8	The Parkinson's disease eâ€diary: Developing a clinical and research tool for the digital age. Movement Disorders, 2019, 34, 676-681.	2.2	43
9	Subthalamic deep brain stimulation and levodopa in Parkinson's disease: a meta-analysis of combined effects. Journal of Neurology, 2019, 266, 289-297.	1.8	39
10	Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitiveâ€enhancing medications. Movement Disorders, 2018, 33, 1769-1776.	2.2	36
11	Technology-based assessment of motor and nonmotor phenomena in Parkinson disease. Expert Review of Neurotherapeutics, 2018, 18, 825-845.	1.4	31
12	COVID-19 and Guillain-Barre Syndrome: a systematic review of case reports. Wellcome Open Research, 2020, 5, 107.	0.9	31
13	Orthostatic hypotension in Parkinson disease: Impact on health care utilization. Parkinsonism and Related Disorders, 2018, 47, 45-49.	1.1	30
14	Small intestinal bacterial overgrowth in Parkinson's disease: TribulationsÂof a trial. Parkinsonism and Related Disorders, 2018, 54, 110-112.	1.1	29
15	The power in numbers: Gut microbiota in Parkinson's disease. Movement Disorders, 2015, 30, 296-298.	2.2	25
16	Phenotype-Agnostic Molecular Subtyping of Neurodegenerative Disorders: The Cincinnati Cohort Biomarker Program (CCBP). Frontiers in Aging Neuroscience, 2020, 12, 553635.	1.7	22
17	COVID-19 and Guillain-Barre Syndrome: a systematic review of case reports. Wellcome Open Research, 2020, 5, 107.	0.9	19
18	Nonâ€Motor Fluctuations in Parkinson's Disease: Validation of the Nonâ€Motor Fluctuation Assessment Questionnaire. Movement Disorders, 2021, 36, 1392-1400.	2.2	16

JOAQUIN A VIZCARRA

#	Article	IF	CITATIONS
19	Association of Orthostatic Hypotension With Cerebral Atrophy in Patients With Lewy Body Disorders. Neurology, 2021, 97, e814-e824.	1.5	14
20	OnabotulinumtoxinA and cognitive behavioral therapy in functional dystonia: A pilot randomized clinical trial. Parkinsonism and Related Disorders, 2019, 63, 174-178.	1.1	13
21	Movement disorders associated with neuronal antibodies: a data-driven approach. Journal of Neurology, 2022, 269, 3511-3521.	1.8	10
22	Genetic parkinsonisms and cancer: a systematic review and meta-analysis. Reviews in the Neurosciences, 2021, 32, 159-167.	1.4	8
23	Development and Validation of the Orthostatic Tremor Severity and Disability Scale (<scp>OT</scp> â€10). Movement Disorders, 2020, 35, 1796-1801.	2.2	7
24	Childhood-Onset Hereditary Spastic Paraplegia (HSP): A Case Series and Review of Literature. Pediatric Neurology, 2022, 130, 7-13.	1.0	7
25	Internal Versus External Frame of Reference in Functional Movement Disorders. Journal of Neuropsychiatry and Clinical Neurosciences, 2020, 32, 67-72.	0.9	5
26	Treatment Issues in Multiple Sclerosis in Latin America. Neuroepidemiology, 2015, 44, 66-68.	1.1	4
27	Author response: Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. Neurology, 2020, 94, 144-145.	1.5	2
28	Impact of behavioral side effects on the management of Parkinson patients treated with dopamine agonists. Clinical Parkinsonism & Related Disorders, 2021, 4, 100091.	0.5	2
29	Update on Nodopathies of the Peripheral Nerve. Current Treatment Options in Neurology, 2021, 23, 1.	0.7	1
30	Quality of life in upper airway resistance syndrome. Journal of Clinical Sleep Medicine, 2021, , .	1.4	0